Skip to main content

Myeloproliferative Neoplasms clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for
  • A Study of Oral LY3410738 in Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

    open to eligible people ages 18 years and up

    This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

    Sacramento, California and other locations

  • EVERYCHILD PROTOCOL

    “A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY”

    open to eligible people ages up to 25 years

    This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

    Sacramento, California and other locations

Our lead scientists for Myeloproliferative Neoplasms research studies include .

Last updated: